{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:30:56Z","timestamp":1790289056057,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1-3","license":[{"start":{"date-parts":[[2009,2,18]],"date-time":"2009-02-18T00:00:00Z","timestamp":1234915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s12026-009-8107-8","type":"journal-article","created":{"date-parts":[[2009,2,17]],"date-time":"2009-02-17T19:33:07Z","timestamp":1234899187000},"page":"150-159","source":"Crossref","is-referenced-by-count":31,"title":["Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID"],"prefix":"10.1007","volume":"44","author":[{"given":"Alessandro","family":"Aiuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immacolata","family":"Brigida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ferrua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Marktel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Grazia","family":"Roncarolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,18]]},"reference":[{"key":"8107_CR1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ni0402-318","volume":"3","author":"C Bordignon","year":"2002","unstructured":"Bordignon C, Roncarolo MG. Therapeutic applications for hematopoietic stem cell gene transfer. Nat Immunol. 2002;3:318\u201321.","journal-title":"Nat Immunol"},{"key":"8107_CR2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.0105-2896.2005.00223.x","volume":"203","author":"A Fischer","year":"2005","unstructured":"Fischer A, Le Deist F, Hacein-Bey-Abina S, Andre-Schmutz I, Basile Gde S, de Villartay JP, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev. 2005;203:98\u2013109.","journal-title":"Immunol Rev"},{"key":"8107_CR3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bmt.1705895","volume":"41","author":"DB Kohn","year":"2008","unstructured":"Kohn DB. Gene therapy for childhood immunological diseases. Bone Marrow Transplant. 2008;41:199\u2013205.","journal-title":"Bone Marrow Transplant"},{"key":"8107_CR4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00130832-200312000-00007","volume":"3","author":"A Aiuti","year":"2003","unstructured":"Aiuti A, Ficara F, Cattaneo F, Bordignon C, Roncarolo MG. Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol. 2003;3:461\u20136.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"8107_CR5","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.gt.3303033","volume":"14","author":"A Aiuti","year":"2007","unstructured":"Aiuti A, Bachoud-Levi AC, Blesch A, Brenner MK, Cattaneo F, Chiocca EA, et al. Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007;14:1555\u201363.","journal-title":"Gene Ther"},{"key":"8107_CR6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/oso\/9780195147742.003.0012","volume-title":"Primary immunodeficiency diseases","author":"R Hirschorn","year":"2006","unstructured":"Hirschorn R, Candotti F. Immunodeficiency due to defects of purine metabolism. In: Ochs H, Smith C, Puck J, editors. Primary immunodeficiency diseases. Oxford: Oxford University Press; 2006. p. 169\u201396."},{"key":"8107_CR7","first-page":"291","volume":"35","author":"MS Hershfield","year":"1998","unstructured":"Hershfield MS. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin Hematol. 1998;35:291\u20138.","journal-title":"Semin Hematol"},{"key":"8107_CR8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.12.009","volume":"123","author":"C Booth","year":"2007","unstructured":"Booth C, Hershfield M, Notarangelo L, Buckley R, Hoenig M, Mahlaoui N, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin immunol. 2007;123:139\u201347.","journal-title":"Clin immunol"},{"key":"8107_CR9","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2006-07-034678","volume":"109","author":"M Honig","year":"2006","unstructured":"Honig M, Albert MH, Schulz A, Sparber-Sauer M, Schutz C, Belohradsky B, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood. 2006;109:3595\u2013602.","journal-title":"Blood"},{"key":"8107_CR10","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1126\/science.1848369","volume":"251","author":"G Ferrari","year":"1991","unstructured":"Ferrari G, Rossini S, Giavazzi R, Maggioni D, Nobili N, Soldati M, et al. An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science. 1991;251:1363\u20136.","journal-title":"Science"},{"key":"8107_CR11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/hum.2006.17.253","volume":"17","author":"C Baum","year":"2006","unstructured":"Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther. 2006;17:253\u201363.","journal-title":"Hum Gene Ther"},{"key":"8107_CR12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","volume":"12","author":"MG Ott","year":"2006","unstructured":"Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401\u20139.","journal-title":"Nat Med"},{"key":"8107_CR13","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132\u201342.","journal-title":"J Clin Invest"},{"key":"8107_CR14","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","volume":"118","author":"SJ Howe","year":"2008","unstructured":"Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118:3143\u201350.","journal-title":"J Clin Invest"},{"key":"8107_CR15","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1172\/JCI31666","volume":"117","author":"A Aiuti","year":"2007","unstructured":"Aiuti A, Cassani B, Andolfi G, Mirolo M, Biasco L, Recchia A, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007;117:2233\u201340.","journal-title":"J Clin Invest"},{"key":"8107_CR16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2006-06-031476","volume":"109","author":"BC Engel","year":"2007","unstructured":"Engel BC, Podsakoff GM, Ireland JL, Smogorzewska EM, Carbonaro DA, Wilson K, et al. Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report. Blood. 2007;109:503\u20136.","journal-title":"Blood"},{"key":"8107_CR17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","volume":"270","author":"RM Blaese","year":"1995","unstructured":"Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4\u00a0years. Science. 1995;270:475\u201380.","journal-title":"Science"},{"key":"8107_CR18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.270.5235.470","volume":"270","author":"C Bordignon","year":"1995","unstructured":"Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science. 1995;270:470\u20135.","journal-title":"Science"},{"key":"8107_CR19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.V91.1.30","volume":"91","author":"M Onodera","year":"1998","unstructured":"Onodera M, Ariga T, Kawamura N, Kobayashi I, Ohtsu M, Yamada M, et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood. 1998;91:30\u20136.","journal-title":"Blood"},{"key":"8107_CR20","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","volume":"101","author":"LM Muul","year":"2003","unstructured":"Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, et al. Persistence and expression of the adenosine deaminase gene for 12\u00a0years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 2003;101:2563\u20139.","journal-title":"Blood"},{"key":"8107_CR21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm0502-423","volume":"8","author":"A Aiuti","year":"2002","unstructured":"Aiuti A, Vai S, Mortellaro A, Casorati G, Ficara F, Andolfi G, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002;8:423\u20135.","journal-title":"Nat Med"},{"key":"8107_CR22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nm0798-775","volume":"4","author":"DB Kohn","year":"1998","unstructured":"Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34\u00a0+\u00a0cells in ADA-deficient SCID neonates. Nat Med. 1998;4:775\u201380.","journal-title":"Nat Med"},{"key":"8107_CR23","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/nm1095-1017","volume":"1","author":"DB Kohn","year":"1995","unstructured":"Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med. 1995;1:1017\u201323.","journal-title":"Nat Med"},{"key":"8107_CR24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nm844","volume":"9","author":"M Schmidt","year":"2003","unstructured":"Schmidt M, Carbonaro DA, Speckmann C, Wissler M, Bohnsack J, Elder M, et al. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Nat Med. 2003;9:463\u20138.","journal-title":"Nat Med"},{"key":"8107_CR25","first-page":"3646","volume":"91","author":"E Haddad","year":"1998","unstructured":"Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana CM, Morgan G, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 1998;91:3646\u201353.","journal-title":"Blood"},{"key":"8107_CR26","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1089\/10430349950017464","volume":"10","author":"RD Huhn","year":"1999","unstructured":"Huhn RD, Tisdale JF, Agricola B, Metzger ME, Donahue RE, Dunbar CE. Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum Gene Ther. 1999;10:1783\u201390.","journal-title":"Hum Gene Ther"},{"key":"8107_CR27","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.V94.7.2271.419k41_2271_2286","volume":"94","author":"M Rosenzweig","year":"1999","unstructured":"Rosenzweig M, MacVittie TJ, Harper D, Hempel D, Glickman RL, Johnson RP, et al. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood. 1999;94:2271\u201386.","journal-title":"Blood"},{"key":"8107_CR28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-0502(02)00038-1","volume":"27","author":"S Slavin","year":"2002","unstructured":"Slavin S, Aker M, Shapira MY, Panigrahi S, Gabriel C, Or R. Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals. Transfus Apher Sci. 2002;27:159\u201366.","journal-title":"Transfus Apher Sci"},{"key":"8107_CR29","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1182\/blood-2003-08-2935","volume":"104","author":"K Kuramoto","year":"2004","unstructured":"Kuramoto K, Follman D, Hematti P, Sellers S, Laukkanen MO, Seggewiss R, et al. The impact of low-dose busulfan on clonal dynamics in nonhuman primates. Blood. 2004;104:1273\u201380.","journal-title":"Blood"},{"key":"8107_CR30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1702371","volume":"25","author":"AM Bolinger","year":"2000","unstructured":"Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 2000;25:925\u201330.","journal-title":"Bone Marrow Transplant"},{"key":"8107_CR31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/1521-2254(200105\/06)3:3<219::AID-JGM184>3.0.CO;2-E","volume":"3","author":"JS Dando","year":"2001","unstructured":"Dando JS, Aiuti A, Deola S, Ficara F, Bordignon C. Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34+ cells. J Gene Med. 2001;3:219\u201327.","journal-title":"J Gene Med"},{"key":"8107_CR32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1749-6632.1999.tb08457.x","volume":"872","author":"DA Williams","year":"1999","unstructured":"Williams DA. Retroviral-fibronectin interactions in transduction of mammalian cells. Ann N Y Acad Sci. 1999;872:109\u201313. discussion 113\u2013104.","journal-title":"Ann N Y Acad Sci"},{"key":"8107_CR33","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","volume":"296","author":"A Aiuti","year":"2002","unstructured":"Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410\u20133.","journal-title":"Science"},{"key":"8107_CR34","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ymthe.2004.08.014","volume":"10","author":"F Ficara","year":"2004","unstructured":"Ficara F, Superchi DB, Hernandez RJ, Mocchetti C, Carballido-Perrig N, Andolfi G, et al. IL\u20133 or IL\u20137 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential. Mol Ther. 2004;10:1096\u2013108.","journal-title":"Mol Ther"},{"key":"8107_CR35","doi-asserted-by":"crossref","unstructured":"Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Long-term safety and efficacy of gene therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency. New Engl J Med. 2009;360:447\u201358.","DOI":"10.1056\/NEJMoa0805817"},{"key":"8107_CR36","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/blood-2007-05-092429","volume":"111","author":"B Cassani","year":"2008","unstructured":"Cassani B, Mirolo M, Cattaneo F, Benninghoff U, Hershfield M, Carlucci F, et al. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood. 2008;111:4209\u201319.","journal-title":"Blood"},{"key":"8107_CR37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2006.06.007","volume":"14","author":"HB Gaspar","year":"2006","unstructured":"Gaspar HB, Bjorkegren E, Parsley K, Gilmour KC, King D, Sinclair J, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 2006;14:505\u201313.","journal-title":"Mol Ther"},{"key":"8107_CR38","doi-asserted-by":"crossref","first-page":"S418","DOI":"10.1016\/j.ymthe.2006.08.1190","volume":"13","author":"M Otsu","year":"2006","unstructured":"Otsu M, Nakajima M, Kida M, Maeyama Y, Toita N, Hatano N, et al. Stem cell gene therapy with no pre-conditioning for the ADA-deficiency patients leads to generalized detoxification and delayed, but steady hematological reconstitution. Mol Ther. 2006;13:S418. (Abstract).","journal-title":"Mol Ther"},{"key":"8107_CR39","first-page":"S111","volume":"16","author":"R Sokolic","year":"2008","unstructured":"Sokolic R, Podsakoff G, Muul L, Engel B, Jagadeesh J, Garabedian E, et al. Myelosupression and withdrawal of PEG-ADA lead to superior results after gene therapy for adenosine deaminase deficiency (ADA-SCID). Mol Ther. 2008;16:S111. (Abstract).","journal-title":"Mol Ther"},{"key":"8107_CR40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.1091667","volume":"303","author":"UP Dave","year":"2004","unstructured":"Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science. 2004;303:333.","journal-title":"Science"},{"key":"8107_CR41","doi-asserted-by":"crossref","first-page":"11730","DOI":"10.1073\/pnas.0603635103","volume":"103","author":"Y Shou","year":"2006","unstructured":"Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA. 2006;103:11730\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8107_CR42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/76095","volume":"25","author":"A Follenzi","year":"2000","unstructured":"Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet. 2000;25:217\u201322.","journal-title":"Nat Genet"},{"key":"8107_CR43","doi-asserted-by":"crossref","unstructured":"Mortellaro A, Hernandez RJ, Guerrini MM, Carlucci F, Tabucchi A, Ponzoni M, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood. 2006;108:2979\u201388.","DOI":"10.1182\/blood-2006-05-023507"},{"key":"8107_CR44","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2004-03-0798","volume":"105","author":"M Palma De","year":"2005","unstructured":"De Palma M, Montini E, de Sio FR, Benedicenti F, Gentile A, Medico E, et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood. 2005;105:2307\u201315.","journal-title":"Blood"},{"key":"8107_CR45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","volume":"24","author":"E Montini","year":"2006","unstructured":"Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24:687\u201396.","journal-title":"Nat Biotechnol"},{"key":"8107_CR46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/14712598.8.2.181","volume":"8","author":"A Galy","year":"2008","unstructured":"Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther. 2008;8:181\u201390.","journal-title":"Expert Opin Biol Ther"},{"key":"8107_CR47","doi-asserted-by":"crossref","unstructured":"Dupr\u00e9 L, Marangoni F, Scaramuzza S, Trifari S, Hernandez RJ, Aiuti A, et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter\/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther. 2006;17:303\u201313.","DOI":"10.1089\/hum.2006.17.303"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-009-8107-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12026-009-8107-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-009-8107-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T17:57:11Z","timestamp":1710093431000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12026-009-8107-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,18]]},"references-count":47,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["8107"],"URL":"https:\/\/doi.org\/10.1007\/s12026-009-8107-8","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,18]]}}}